Bristol Myers: new data for multiple sclerosis
(CercleFinance.com) - Bristol Myers Squibb has presented new Zeposia (ozanimod) data on long-term disease progression in patients with relapsing forms of multiple sclerosis.
Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression-independent relapse activity (PIRA) and relapse-associated worsening (RAW) after eight years of follow-up.
The first interim report from the Phase 3b ENLIGHTEN trial shows that almost half of patients with early relapsing multiple sclerosis show clinically significant improvement in cognitive functioning compared to baseline after one year of Zeposia treatment.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Late-breaking data from the DAYBREAK and RADIANCE trials show similarly low rates of progression-independent relapse activity (PIRA) and relapse-associated worsening (RAW) after eight years of follow-up.
The first interim report from the Phase 3b ENLIGHTEN trial shows that almost half of patients with early relapsing multiple sclerosis show clinically significant improvement in cognitive functioning compared to baseline after one year of Zeposia treatment.
Copyright (c) 2023 CercleFinance.com. All rights reserved.